ATG-301

ATG-301 is a transdermal “SmartPatch” formulation being developed by Ategenos Pharmaceuticals as a reformulated version of a critical-dose oral therapy for sustained-release delivery through the skin. It is designed to provide controlled, non-oral administration of an existing active pharmaceutical ingredient by embedding it in a proprietary patch matrix that enables continuous systemic exposure while bypassing first-pass metabolism and improving ease of use for patients who struggle with oral dosing.[5] Publicly available sources do not disclose the specific active ingredient, target, or indication for ATG-301, and it is best regarded as an investigational, reformulation-focused drug–device product candidate built on Ategenos’s transdermal platform.[5]